News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bombay HC to Begin Hearing in Bayer AG (BAYN.DE)'s Case Against IPAB's CL Order on Nexavar Today


10/29/2013 7:30:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The hearing in the high voltage Nexavar case by German drug major Bayer against India's first ever compulsory license (CL) to Natco Pharma will begin in Bombay High Court on October 29. In this case, the multinational drug company is challenging the Intellectual Property Appellate Board (IPAB)'s order in March this year in which the IPAB, Chennai had upheld India’s first ever compulsory license (CL) issued to Hyderabad-based generic drug company Natco Pharma for manufacturing and marketing generic copies of Bayer's patented kidney cancer drug Nexavar.

Help employers find you! Check out all the jobs and post your resume.

Read at PharmaBiz


comments powered by Disqus
PharmaBiz
Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES